Eli Lilly jumps after Q1 2026 EPS surge and raised full-year guidance
Eli Lilly shares rose after the company reported Q1 2026 results showing net income of $7.4 billion and EPS of $8.26, up from $2.8 billion and $3.06 a year ago. The company also raised full-year guidance, citing continued momentum led by Mounjaro and Zepbound.
1. What’s moving the stock today
Eli Lilly stock is higher today after the company released first-quarter 2026 results and raised its full-year outlook. The quarter featured a sharp year-over-year jump in profitability, with net income of $7.4 billion and EPS of $8.26 versus net income of $2.8 billion and EPS of $3.06 in Q1 2025, reinforcing the market’s view that Lilly’s growth engine remains intact. (prnewswire.com)
2. Key drivers investors are reacting to
The earnings release highlighted continued strength in Lilly’s core portfolio, with Key Products revenue reaching $13.4 billion in Q1 2026, led by Mounjaro and Zepbound. For investors focused on the GLP-1 obesity/diabetes franchise, the combination of accelerating profit and management’s decision to lift full-year guidance is the main bullish read-through behind the move. (prnewswire.com)
3. What happens next
Lilly’s Q1 2026 earnings call is scheduled for April 30, 2026 at 10:00 a.m. ET, where investors will look for details on demand, supply ramp, pricing dynamics, and how much of the guidance raise is driven by volume versus mix or other factors. Any incremental commentary on the durability of Mounjaro/Zepbound growth and expected pricing headwinds into the rest of 2026 could determine whether today’s rally holds. (investor.lilly.com)